AI Article Synopsis
- This study analyzes leukemia and lymphoma mortality rates in Brazil from 2010 to 2016, using health data to understand trends and population characteristics.
- It finds that leukemia has a significantly higher mortality rate (1.76 times) than lymphoma, with an annual increase of 1.2% in leukemia deaths.
- The research identifies that older age, male gender, being white, and living in the South and Southeast regions are associated with higher mortality rates, with lower social inequality regions showing more deaths for both diseases.
Article Abstract
In the last decades, few epidemiological studies have discussed the mortality rates due to leukemia and lymphoma in Brazil. This study analyzes the evolution over time of the number of deaths due to leukemia and lymphoma in Brazil, between 2010 and 2016, considering the population's characteristics and spatial distribution. This is a retrospective epidemiological study based on data obtained in the Brazilian Health Informatics Department (DATASUS), associated with the quantitative population. We created choropleth maps and predictive models of mortality rates, using the incidence rate ratio (IRR) to measure the size of the effect. Leukemia had a 1.76 higher mortality rate than lymphoma. Leukemia mortality trends increased by 1.2% per year between 2010 and 2016. Regions with the lowest social inequality had higher mortality rates for both diseases. There was a difference between peaks with higher chances of death due to leukemia (> 60 years) and lymphoma (> 70 years). Older age, male, white, and South and Southeast regions were associated with higher mortality by leukemia or lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/0102-311x00077119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
Ann Hematol
January 2025
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone.
View Article and Find Full Text PDFThe Many Faces of Philadelphia: A Mature T-Cell Lymphoma with Variant Philadelphia-Translocation and Duplication of the Philadelphia Chromosome.
Hematol Rep
January 2025
Department of 1st Internal Medicine, Medical School, University of Pécs, Ifjúság Str. 13, 7624 Pécs, Hungary.
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell lymphoma that is usually associated with poor prognosis and short overall survival. We present a case of a 61-year-old woman presenting with T-PLL and the leukemic cells harboring (-breakpoint cluster region; -ABL protooncogene 1) fusion transcripts as the result of a variant of t(9;22)(q34;q11) called Philadelphia translocation: t(9;22;18)(q34;q11;q21). Sequencing revealed a rare transcript with an exon 6 breakpoint corresponding to e6a2 transcripts, which has thus far been reported in only 26 cases of leukemias.
View Article and Find Full Text PDFA Commensurate Prior Model With Random Effects for Survival and Competing Risk Outcomes to Accommodate Historical Controls.
Pharm Stat
January 2025
Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Clinical trials (CTs) often suffer from small sample sizes due to limited budgets and patient enrollment challenges. Using historical data for the CT data analysis may boost statistical power and reduce the required sample size. Existing methods on borrowing information from historical data with right-censored outcomes did not consider matching between historical data and CT data to reduce the heterogeneity.
View Article and Find Full Text PDFPresence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
Leuk Lymphoma
January 2025
Faculty of Pharmacy, Center for Biomolecular Pharmaceutical Analyses, University Ss. Cyril and Methodius in Skopje, Skopje, North Macedonia.
The role of next-generation sequencing (NGS) for minimal residual disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is still under consideration. Fifty pediatric patients were prospectively evaluated for specific clonal rearrangements of immunoglobulin and T-cell receptor genes using NGS analysis at diagnosis and on days 33 and 78 from therapy onset. The prognostic value or the NGS-MRD status was analyzed after a median follow-up of 4 years.
View Article and Find Full Text PDFARID1A mutations protect follicular lymphoma from FAS-dependent immune surveillance by reducing RUNX3/ETS1-driven FAS-expression.
Cell Death Differ
January 2025
Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), LMU University Hospital, Munich, Germany.
The cell death receptor FAS and its ligand (FASLG) play crucial roles in the selection of B cells during the germinal center (GC) reaction. Failure to eliminate potentially harmful B cells via FAS can lead to lymphoproliferation and the development of B cell malignancies. The classic form of follicular lymphoma (FL) is a prototypic GC-derived B cell malignancy, characterized by the t(14;18)(q32;q21)IGH::BCL2 translocation and overexpression of antiapoptotic BCL2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!